Dianthus Therapeutics, Inc.
DNTH
주식 순위
#3914
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
주가
$75.21
시가총액
$4.21B
변동 (1일)
4.33%
변동 (1년)
110.98%
국가
US
거래 Dianthus Therapeutics, Inc. (DNTH)
카테고리
Healthcare
Dianthus Therapeutics, Inc. (DNTH)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 3.57
Dianthus Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 3.57입니다. 2023년 말 기준 P/B 비율은 0.32였습니다.
Dianthus Therapeutics, Inc.의 P/B 비율 기록 (2016 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 3.57 | 73.49% |
| 2024 | 2.06 | 549.15% |
| 2023 | 0.32 | -159.46% |
| 2022 | -0.53 | -137.87% |
| 2021 | 1.41 | -41.09% |
| 2020 | 2.39 | -39.79% |
| 2019 | 3.97 | 204.85% |
| 2018 | 1.30 | -87.23% |
| 2017 | 10.21 | -82.03% |
| 2016 | 56.80 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | 74.91% |
US
|
|
| 13.2547 | 270.87% |
US
|
|
| 4.208 | 17.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 72.99% |
NL
|
